Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. - תוצאות חיפוש

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

premia low 0.3/1.5 continuous

pfizer new zealand limited - conjugated estrogens 0.308mg (7.18mg as dessication with lactose; includes a 2.7 % overage; up to an 8% overage used); medroxyprogesterone acetate 1.56mg (includes 4% overage; equiv to 1.5 mg mpa) - coated tablet - active: conjugated estrogens 0.308mg (7.18mg as dessication with lactose; includes a 2.7 % overage; up to an 8% overage used) medroxyprogesterone acetate 1.56mg (includes 4% overage; equiv to 1.5 mg mpa) excipient: calcium phosphate calcium sulfate carnauba wax glyceryl mono-oleate iron oxide yellow lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose povidone powdered cellulose shellac sucrose tekprint black sw-9008 titanium dioxide

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

premia low 0.45/1.5 continuous

pfizer new zealand limited - conjugated estrogens 0.462mg (10.77mg as dessication with lactose; includes 2.7% overage; up to 8 % overage used); medroxyprogesterone acetate 1.56mg (includes 4% overage; equiv to 1.5 mg mpa) - coated tablet - active: conjugated estrogens 0.462mg (10.77mg as dessication with lactose; includes 2.7% overage; up to 8 % overage used) medroxyprogesterone acetate 1.56mg (includes 4% overage; equiv to 1.5 mg mpa) excipient: calcium phosphate calcium sulfate carnauba wax glyceryl mono-oleate iron oxide yellow lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose povidone powdered cellulose shellac sucrose tekprint black sw-9008 titanium dioxide

ישראל - אנגלית - Ministry of Health

rapamune solution

pfizer pharmaceuticals israel ltd - sirolimus - solution (oral) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

benefix

pfizer new zealand limited - nonacog alfa 3000 [iu] (+/- 10% overage) - powder for injection with diluent - 3000 iu - active: nonacog alfa 3000 [iu] (+/- 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

venlafaxine hydrochloride- venlafaxine hydrochloride capsule, extended release

greenstone llc - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder (mdd). efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. venlafaxine hydrochloride extended-release is indicated for the treatment of generalized anxiety disorder (gad). efficacy was established in two 8-week and two 26-week placebo-controlled trials. venlafaxine hydrochloride extended-release is indicated for the treatment of social anxiety disorder (sad), also known as social phobia. efficacy was established in four 12-week and one 26-week, placebo-controlled trials. venlafaxine hydrochloride extended-release is indicated for the treatment of panic disorder (pd), with or without agoraphobia. efficacy was established in two 12-week placebo-controlled trials. hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation the use of maois (intended to treat psychiatric disorders) concomitantly wit